ClinicalTrials.gg
RecruitingNCT06210815Updated Sep 22, 2025

A Study of HLX42 in Advanced/Metastatic Solid Tumors

A Phase 1 interventional study of HLX42 in Solid Tumor and NSCLC, sponsored by Shanghai Henlius Biotech. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma — 10 open to participants now, 15 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Fosun Pharma.

Planned enrollment
14th of 17
102 · median 150
Started
2024
the only one that year
Phase 1
4 of 17
2 open now
Primary completion
2026-09
later than 6 of 14 live
Registered
7th of 17
by date

Among the 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma, this one is the 14th largest by planned enrollment, is the only one that started in 2024, is one of 4 in phase 1, reaches primary completion later than 6 of the 14 other live ones, and was the 7th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

10 of the 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma are open now, in 2 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma, or all of them as a file.
02

Study summary

This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.

Read the detailed description

The first stage: This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42 with escalated doses in the treatment of patients with advanced/metastatic solid tumors. In this study, a 3 + 3 dose escalation method will be adopted, and the patients will be administered with HLX42 at different doses via intravenous infusion. The DLT observation period lasts for 3 weeks after the first administration of HLX42.

The second stage: This is a randimazation, open label, 2 arms, muticentral clinical study, about 30 patients in each arm, the total sample size is about 60. Eligible subjects will be randomized in a 1:1 ratio: Group A: HLX42 2.5 mg/kg; Group B: HLX42 2.0 mg/kg. Stratification: tumor tissue type(adenocarcinoma or squamous carcinoma), EGFR-sensitive mutation status (mutant or wild-type or missing).

03

Conditions studied

  • Solid Tumor and NSCLC
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years and ≤ 75 years at the time of signing the ICF, male or female;
  2. Patients with or cytologically confirmed advanced/ malignant solid tumors, who are to or intolerable with standard treatment, or for which no standard treatment is available(stage 1); Patients with histologically or cytologically confirmed advanced/metastatic malignant NSCLC, who are refractory to or intolerable with standard treatment, or for which no standard treatment is available(stage 2);
  3. At least one as per 1.1;
  4. An performance status score of 0-1;
  5. > 3 months;
  6. Adequate organ functions as confirmed by laboratory tests within 7 days prior to the first administration of the product;
  7. For patients with hepatocellular carcinoma, score must be A;

Exclusion criteria

Exclusion Criteria:

  1. History of other malignant tumors within 2 years prior to the first administration, except for cured cervical carcinoma in situ or cutaneous basal cell carcinoma;
  2. The histopathological type is large cell carcinoma, adenosquamous carcinoma, other types (including but not limited to sarcomatoid carcinoma, lymphoepithelioma-like carcinoma, NUT carcinoma, etc.), or contains neuroendocrine pathological components, etc. (stage 2);
  3. History of (non-infectious) ILD requiring the use of , current ILD, or suspected ILD that cannot be ruled out by imaging at screening;
  4. Subjects who are allergic to protein preparations/ monoclonal antibodies/ any component in the formulation of the product;
  5. Subjects with known previous serious eye disorders;
  6. Active systemic infectious diseases requiring intravenous antibiotics within 2 weeks prior to the first administration of the investigational product;
  7. Any poorly-controlled cardiovascular and cerebrovascular clinical symptoms or diseases;
  8. Patients who have been assessed as unsuitable for inclusion by the investigator, due to , spinal cord compression, or cancerous meningitis with clinical symptoms, or uncontrolled brain or spinal cord that have been evidenced;
  9. Patients who have received long-term systemic steroids treatment (equivalent to prednisone > 10 mg/day) or agents of any other forms, which should be discontinued at least 2 weeks prior to the first infusion of the investigational product;
  10. Patients who have used potent CYP2D6/ inhibitors or inducers within 2 weeks prior to the first administration;
  11. Patients who have history of immunodeficiency, including infection or other acquired or congenital immunodeficiencies, or history of organ transplantation;
  12. Patients with active or infection or HBV/HCV co-infection;
  13. Pregnant or lactating women;
  14. Subjects who are not suitable for participating in this clinical study due to any clinical or laboratory abnormalities or other reasons as assessed by the investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    HLX42

    Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

    Drug: HLX42

Interventions

  • DrugHLX42

    HLX42 is an anti-EGFR monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

    Also known as: Anti-EGFR ADC

06

What researchers measure

Primary outcomes

  1. The Dose-Limiting Toxicity (DLT) of HLX42 within 21 days after the first Administration

    DLT refers to the AEs that are determined to be related to the investigational product by the investigator, whose severity will affect the escalation of dose level. In this study, the DLT observation period lasts for 21 days after the first administration of HLX42.

    Time frame: From first dose to the end of Cycle 1 (each cycle is 3 weeks).

  2. The maximum tolerated dose (MTD) of HLX42

    The highest dose level, at which DLT is observed in no more than one of 6 evaluable patients, is defined as MTD of HLX42.

    Time frame: From first dose to the end of Cycle 1 (each cycle is 3 weeks)

Secondary outcomes

  1. Objective response rate (ORR)

    Percentage of participants with complete response (CR) and partial response (PR) based on investigator assessment.

    Time frame: approximately up to 24 months

  2. Duration of response (DOR)

    Length of time response continued based on investigator's assessment.

    Time frame: approximately up to 24 months.

  3. Progression-free survival (PFS)

    The PFS is defined as the time from the date of enrollment to the date of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause,whichever occurred first.

    Time frame: up to approximately up to 24 months

  4. Overall survival (OS)

    Time from the date of enrollment to the date of death for any cause.

    Time frame: approximately up to 24 months

  5. Cmax

    Maximum serum concentration (Cmax) of HLX42.

    Time frame: Up to 21 days after the first dose

  6. Tmax

    Time to maximum serum concentration (Tmax) of HLX42.

    Time frame: Up to 21 days after the first dose

  7. T1/2

    Half-life (T1/2) of HLX42.

    Time frame: Up to 21 days after the first dose

  8. ADA (anti-drug antibody)

    Incidence and titer of ADA of HLX42.

    Time frame: approximately up to 24 months

  9. Nab (neutralizing antibody)

    Incidence and titer of Nab of HLX42.

    Time frame: approximately up to 24 months

  10. Number of subjects experiencing adverse events

    Frequency and seriousness of treatment emergent adverse events (TEAEs).

    Time frame: Day 1 through 90 days after last dose.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Sep 2026, 29 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 29 months is below that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2024
First posted
Jan 18, 2024
StartActual
Mar 14, 2024
Primary completionEst.
Sep 2, 2026
CompletionEst.
Jun 14, 2027
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06210815
Responsible party
Sponsor
First posted
Jan 18, 2024
Start date
Mar 14, 2024
Primary completion
Sep 2, 2026 (estimated)
Completion
Jun 14, 2027 (estimated)
Last update
Sep 22, 2025

Study contacts

Yilong Wu, Dr.
Contact
syylwu@live.cn
020-83827812
Huajun Chen, Dr.
Contact
chjdoctor@163.com
020-83827812
Yilong Wu, Dr.
principal investigator · Guangdong Provincial People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion